Metropolis Healthcare Ltd posted a steady performance in Q2FY26, with revenue rising 23% year-on-year to ₹429 crore and EBITDA up 19%. The company recorded double-digit growth in patient and test volumes, supported by its preventive health and specialty portfolios. The board approved a 200% dividend for the quarter. Metropolis continues to strengthen its presence in Tier II and III cities, improve margins, and invest in genomics and digital initiatives to enhance efficiency and service quality.

See Full Page